Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer

75% of Patients in Part 1 Experienced Complete Resolution of Radiation Dermatitis Part 2 Data Shows Clinically Relevant Treatment Effect in 100% of Patients on LUT014 vs. 72.7% on Placebo Secondary

Related Keywords

Israel ,Antoni Ribas ,Kostenloser Wertpapierhandel ,Noa Shelach ,Michael Miller ,Lutris Pharma ,Rx Communications Group ,Complete Resolution ,Shows Clinically Relevant Treatment Effect ,Endpoints Support Potential Activity ,Treatment Efficacy ,Radiation Dermatitis ,Common Terminology Criteria ,Adverse Events ,Dermatology Life Quality Index ,Treatment Emergent Adverse Events ,Chief Executive Officer ,Chief Medical Officer ,B Raf Inhibitors ,Epidermal Growth Factor Receptor ,Lutris ,Dharma ,Reports ,Positive ,Line ,Results ,Rom ,Pen ,Label ,Art ,Double ,Blinded ,Hase ,Trial ,Ut014 ,Treat ,Radiation ,Dermatitis ,Patients ,Breast ,Dancer ,